Download Free Medical Pharmacogenetics and Pharmacogenomics PowerPoint Presentation

Pharmacogenetics and Pharmacogenomics PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : Check out this medical PowerPoint presentation titled "Pharmacogenetics and Pharmacogenomics" by Kevin Zbuk, MD.

This medical PowerPoint presentation is about pharmacogenetics and pharmacogenomics, both fields of study that focus on the relationship between an individuals genetic makeup and their response to drugs.

Pharmacogenetics is the study of how variations in an individuals genes can affect their response to drugs. By examining an individuals genetic makeup, researchers can identify genetic variations that may affect how a drug is metabolized, absorbed, or eliminated from the body. This information can be used to tailor drug therapy to an individuals unique genetic profile, optimizing drug efficacy and minimizing side effects.

Pharmacogenomics, on the other hand, is a broader field that involves the study of how an individuals entire genome (i.e., all of their genes) can affect their response to drugs. This involves the use of high-throughput genomic technologies to identify genetic variations that may be associated with drug response, as well as the development of computational methods to analyze and interpret large amounts of genomic data.

Both pharmacogenetics and pharmacogenomics have the potential to improve the safety and efficacy of drug therapy by enabling personalized medicine. However, these fields are still in the early stages of development, and more research is needed to fully understand the complex interactions between genetics and drug response.

Tags : Pharmacogenetics, Pharmacogenomics, pharmaceuticals, pharmaceuticals PowerPoint presentations

Published on : Jun 23, 2023 | Views : 2196 | Downloads : 3

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

Pharmacogenetics and Pharmacogenomics Kevin Zbuk, MD Medical Oncologist Juravinski Cancer Centre McMaster University
Slide 2-

Outline Introduction and definitions Basic concepts Case studies Conclusions
Slide 3-

Pharmacogenetic versus Pharmacogenomic No universally accepted definitions of either Often used interchangeably Pharmacogenetics used for more than 40 years to denote the science about how heritability affects the response to drugs. Pharmacogenomics is new science about how the systematic identification of all the human genes, their products, interindividual variation, intraindividual variation in expression and function over time affects drug response/metabolism etc. The term pharmacogenomics was coined in connection with the human genome project Most use pharmacogenetics to depict the study of single genes and their effects on interindividual differences in (mainly) drug metabolising enzymes, and pharmacogenomics to depict the study of not just single genes but the functions and interactions of all genes in the genome in the overall variability of drugs response
Slide 4-

ppt slide no 4 content not found
Slide 5-

ppt slide no 5 content not found
Slide 6-

Pharmacogenetics “Pharmacogenetics is the study of how genetic variations affect the disposition of drugs, including their metabolism and transport and their safety and efficacy” J. Hoskins et. al NRC 2009
Slide 7-

Pharmacogenetics involves both PK and PD Pharmacokinetic “The process by which a drug is absorbed, distributed, metabolized, and eliminated by the body” Pharmacodynamic “the biochemical and physiological effects of drugs and the mechanisms of their actions”
Slide 8-

Goals of Pharmacogen(etics)omics Maximize drug efficacy Minimize drug toxicity Predict patients who will respond to intervention Aid in new drug development
Slide 9-

The Hope of Pharmacogenomics Individuals genetic makeup with allow selective use of medications such that Efficacy maximized Side effect minimized
Slide 10-

This is the hope/hype
Slide 11-

In the Beginning Mendelian genetics “single gene – single disease” single wild type allele and single disease allele Patterns of inheritance included autosomal dominant (need only one disease allele) and autosomal recessive (need two disease alleles) Followed soon thereafter by additive (co-dominant) model Both alleles contribute to phenotype
Slide 12-

Dominant/Recessive
Slide 13-

Co-dominance
Slide 14-

Empiric observations suggesting Pharmacogenetics important Clinical response to many drugs varies widely amongst individuals Same drug-> same dose -> same indication in different individuals Some respond Some don’t Some don’t respond and have serious toxicity
Slide 15-

EARLY PK EXAMPLES
Slide 16-

The beginning of pharmacogenetics 1950s “Inheritance might explain variation in individuals response and adverse effects from drugs” Motulsty “Pharmacogenetics defined as “study of role of Genetics in drug response” Vogel Most of studies for next several decades of “high penetrance monogenic” gene-drug interactions Def: Monogenetic disease. Mutation at single locus sufficient to result in disorder
Slide 17-

Penetrance Penetrance of a disease-causing mutation is the proportion of individuals with the mutation who exhibit clinical symptoms. Eg. if a mutation in the gene responsible for a particular autosomal dominantdisorder has 95% penetrance, then 95% of those with the mutation will develop the disease, while 5% will not.
Slide 18-

Victor McKusick Established Online Mendelian Inheritance in Man in early 80s Categorized majority of Mendelian Disorders Became very clear that there are many different disease alleles for many disorders (allelic heterogeneity) Recently many disorders have associated modifier genes that modify disease phenotype Eg. Age-of-onset and severity
Slide 19-

ppt slide no 19 content not found
Slide 20-

Example 1- Success of Pharmacogenetics in Oncology TPMT
Slide 21-

TPMT Main metabolizer of chemotherapeutic agents 6MP and azothiopurine (used mainly in blood based malignancies) TPMT deficiency leads to severe toxicity associated with treatment (potential mortality)
Slide 22-

TPMT enzyme activity distribution
Slide 23-

Hematologic toxicity according to TPMT genotype
Slide 24-

Evans Nature Reviews Cancer 2006
Slide 25-

FDA approved pharmacogenetic tests These genes all modulate Pharmokinetics
Slide 26-

Contribution of High Penetrance Monogenic Model to PG Contribution likely not as large as initially anticipated For most pharmacologic traits might be 15-20% at most Could consider this penetrance Redundancy likely a major contributing factor MANY ENZYMES INVOLVED IN DRUG METABOLISM WITH MANY ALTERNATE PATHWAYS Dichotomous disease versus quantitative trait Much more likely polygenic model with gene-environment interactions
Slide 27-

Some of it ain’t genetic Age Co-morbidities Renal and hepatic function (dysfunction) Concomitant medications Diet and smoking
Slide 28-

Common Disease Common Variant Hypothesis Most complex diseases are strongly influenced by combination of frequent alleles that each only exert modest effect Polygenic Model (lnheritance)
Slide 29-

ppt slide no 29 content not found
Slide 30-

Approach to polygenic pharmacogenomic traits
Slide 31-

Polygenic Model and PG Elucidation unlikely possible before advances in genomics Technologic advances High throughput sequencing of DNA Affordable genotyping of 100ks to 1-2M SNPs Genomic knowledge advances: Especially Human Genome Project and HapMap Projects
Slide 32-

ppt slide no 32 content not found
Slide 33-

ppt slide no 33 content not found
Slide 34-

ppt slide no 34 content not found
Slide 35-

ppt slide no 35 content not found
Slide 36-

ppt slide no 36 content not found
Slide 37-

ppt slide no 37 content not found
Slide 38-

ppt slide no 38 content not found
Slide 39-

Cost of Genotyping In 2005 (5 years ago!) $1600 to genotype 250K SNPs in one individual 2009 $250 to genotype >1Million SNPs 2014 -$200-250 to genotype >5 millions SNPs
Slide 40-

ppt slide no 40 content not found
Slide 41-

ppt slide no 41 content not found
Slide 42-

ppt slide no 42 content not found
Slide 43-

Hapmap project There are an estimated 10 million SNPs with MAF >1% Hapmap project genotyped Chinese, Japanese, African and European individuals (families)
Slide 44-

HapMap Project
Slide 45-

ppt slide no 45 content not found
Slide 46-

A more in depth look at PK in clinical practice Tamoxifen use and CYP2D6
Slide 47-

Tamoxifen metabolism Needs to be converted to endoxifen to be active catalysed by the polymorphic enzyme cytochrome P450 2D6 (CYP2D6) 6-10% European population deficient in this enzyme Efficacy of tamoxifen likely low in this population Suggests consider alterative treatments
Slide 48-

J. Hoskins et. al NRC 2009
Slide 49-

About the CYPs Membrane bound enzymatic proteins Involved in oxidation, peroxidation and reductive metabolism Responsible for >90% of drug transformation Greater than 50 different CYP genes encoding 50 different proteins CYP2D6 present mainly in liver and a major player in drug metabolism from antidepressants to antihypertensive to chemotherapy
Slide 50-

Evolution of CYP nomenclature Initially astute clinical observation of unusual drug response Such responses then found to be heritable Early example of phenotype to genotype approach CYP2D6 polymorphism the first described Increasing recognition of poor metabolizer phenotype occurred at time that genotyping technology in evolution
Slide 51-

About CYP2D6 Location 22q 13.1 P arm Q arm
Slide 52-

CYP2D6 alleles There are >70 described in this gene Bottom line: variants either cause no change, decrease somewhat, or significantly decrease metabolism Extensive metabolizers ( EM), intermediate (IM) metabolizers, and poor metabolizers (PM) EM is the standard metabolism allele against which others are compared (consider it the wild type)
Slide 53-

Hoskins et al. Nature Reviews Cancer 2009
Slide 54-

CYP2D6 alleles Copy Number Variation Throughout the genome there are areas of DNA that are represented in variable copies in individuals (CNV) CYP2D6 is one such area Up to 16 copies seen in some individuals “NORMAL VARIANT” ULTRARAPID METABOLIZERS
Slide 55-

Consequence of CYP2D6 alleles? EM/EM or EM/IM(PM) normal metabolizers IM/IM or IM/PM intermediate metabolizers PM/PM poor metabolizers Poor/(Intermediate) metabolizers have much lower levels of endoxifen than intermediate/ rapid metabolizers
Slide 56-

CYP2D6 Genotype and clinical outcomes Several (small trials) have suggested decreased efficacy of Tamoxifen in poor (intermediate) metabolizers both in adjuvant therapy and in treatment of metastatic disease (see Hoskins NRC 2009 for details) All retrospective Largest was only statistically significant association in univariate analysis In additions several trials have not confirmed these results
Slide 57-

Reasons for discordant results in CYP2D6 trials Did not genotype many of the rarer poor metabolizer alleles Did not account for concurrent use of other drugs metabolized by CYP2D6 in many cases Different dose of Tamoxifen in several trials Did not assay endoxifen levels Power (poor metabolizers rare) Unknown variants in other genes whose products involved in tamoxifen metabolism
Slide 58-

So what is needed to clarify the issue of relevance of CYP2D6 genotype and clinical relevance? Large randomized trial that compares standard dosing of tamoxifen to genotype adjusted dosing Until that point clinical utility of testing (commerically available) unclear Should recommend avoiding SSRIs that inhibit CYP2D6 significantly (see later)
Slide 59-

Provocative thoughts In post-menopausal breast cancer tamoxifen is falling out of favor due to the efficacy of Aromatase Inhibitors (inhibit extragonadal production of estrogen) AI shows increased efficacy c/w tamoxifen BUT MUCH MORE EXPENSIVE AND DIFFERENT S/E PROFILE Some suggestion that increased efficacy of AI completely explained by decreased efficacy of Tamoxifen in CYP2D6 IM and PM Punglia (2008) JNCI
Slide 60-

More relevant to pre-menopausal woman Can’t use AI alone In poor metabolizer could consider Increased dose??? Alternative estrogen receptor modulator not metabolized by CYP2D6 (eg. raloxifen) Consider AI with ovarian ablation (chemical or otherwise)
Slide 61-

Ethnic Differences in IM and PM of CYP2D6 PM alleles more common in European population IM alleles much more common in East Asian and African population In East Asians Intermediate Metabolizers show similar in vitro CYP2D6 activity c/w Poor Metabolizers in European populations Gene-gene or gene-environment interactions
Slide 62-

Drug Co-administration Antidepressant use common in breast cancer patients Depression more common in breast cancer patients and antidepressant often used to treat how flashes associated with tamoxifen use SSRIs (eg. Fluoxetine and paroxetine) inhibit CYP2D6 Level of inhibition varies between different drugs with paroxetine having most inhibition and venlafaxine causing none Kelly et al. BMJ 2010 Population based cohort study of women receiving tamoxifen adjuvantly for treatment breast cancer Mortality from breast cancer increased in group using paroxtetine concurrent with tamoxifen
Slide 63-

Irinotecan – PK example in Colon Cancer Excreted after conjugation (glucuronidation) by UGT1A1 TATA element (consists of TA repeats) in UGT1A1 promoter shows correlation with transcription levels More repeats lower transcription levels An example of a non-SNP variant with clinical relevance Homozygosity for 7-repeat allele, also known as UGT1A1*28 associated with severe toxicity (diarrhea and low WBC counts mainly) Results have been somewhat inconsistent but meta-analysis confirms same especially with higher doses of Irinotecan Homozygosity only in 5-15% of individuals
Slide 64-

PD example in Colon Cancer Treatment EGFR inhibitors used in treatment of advanced colon cancer (eg. Cetuximab) Tumors with k-RAS (and probably BRAF) mutations will NOT respond to EGFR inhibition Nature Rev. Cancer July 2009
Slide 65-

Review Paper by Pare et al.
Slide 66-

Effect of Clopidogrel as Compared with Placebo on Clinical Outcomes among Patients with Acute Coronary Syndromes in the CURE trial, Stratified According to Metabolizer Phenotype. Paré G et al. N Engl J Med 2010;363:1704-1714
Slide 67-

Kaplan–Meier Curves for Event-free Survival According to CYP2C19 Loss-of-Function and Gain-of-Function Allele Carrier Status among European and Latin American Patients with Acute Coronary Syndromes in the CURE Trial. Paré G et al. N Engl J Med 2010;363:1704-1714
Slide 68-

Effect of Clopidogrel as Compared with Placebo on Clinical Outcomes among Patients with Atrial Fibrillation in ACTIVE A, Stratified According to Metabolizer Phenotype. Paré G et al. N Engl J Med 2010;363:1704-1714
Slide 69-

Kaplan–Meier Curves for Event-free Survival According to CYP2C19 Loss-of-Function and Gain-of-Function Allele Carrier Status among European Patients with Atrial Fibrillation in ACTIVE A. Paré G et al. N Engl J Med 2010;363:1704-1714
Slide 70-

Baseline Characteristics of Genotyped Patients in the CURE and ACTIVE A Trials. Paré G et al. N Engl J Med 2010;363:1704-1714
Slide 71-

Why is pharmacogenomics not widely utilized in the clinic It required a shift in clinician attitude and beliefs “not one dose fits all” Paucity of studies demonstrating improved clinical benefit from use of pharmacogenomic data Still much to be learned Even some of the black block warnings currently on drug labels may be overcalls of importance Genome wide interrogation will likely be important to get the entire picture
Slide 72-

Conclusion Genetic variation contributes to inter-individual differences in drug response phenotype at every pharmacologic step Through individualized treatments, pharmacogenetics and pharmacogenomics are expected to lead to: Better, safer drugs the first time More accurate methods of determining appropriate drug dosages Pharmacogenomics offers unprecedented opportunities to understand the genetic architecture of drug response HOWEVER IN MANY CASES NOT YET READY FOR PRIME TIME!!!